Drug Profile
Research programme: Amyloid beta small molecule pharmacological chaperones - Cantabio/NovAliX
Alternative Names: Aβ peptide pharmacological chaperones - Cantabio/NovAliX; Aβ peptide small molecule chaperones - Cantabio/NovAliX; CB 301Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Cantabio Pharmaceuticals
- Class Antidementias; Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 31 Aug 2023 Research programme: Amyloid beta small molecule pharmacological chaperones is still in preclinical development for Alzheimer's disease in USA (Cantabio Pharmaceuticals Pipeline, August 2023)
- 28 May 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 12 Apr 2016 Preclinical trials in Alzheimer's disease in USA (unspecified route) before April 2016